pan-genotype HCV NS3/4A protease inhibitor
proj. oral QD dosing, well-tolerated in rodent
deuteration reduced CYP TDI
J. Med. Chem., Nov. 23, 2020
Bristol-Myers Squibb, NJ + MA + CT + IN
Bristol-Myers Squibb (BMS) pan-genotype HCV NS3/4A protease inhibitor